BioScience under the Big Sky

Winter II 2024 Newsletter


Hall of Fame

Montana BioScience Alliance Hall of Fame 2023

Our 2023 Hall of Fame inductee is Blake Wiedenheft, Ph.D., Professor of Microbiology and Cell Biology, Montana State University, Bozeman

For Dr. Blake Wiedenheft, science is the ultimate adventure. The Montana native was raised in Fort Peck, received his B.S. and Ph.D. from Montana State University in Bozeman, and is now conducting cutting-edge research from his lab at MSU.

Dr. Wiedenheft started at MSU intending to go on to medical school. However, when he met two senior professors – Dr. Trevor Douglas and Dr. Mark Young who were part of MSU’s Thermal Biology Institute – his plans changed.

“They showed me that science was more about creativity and imagination than it was about just memorization,” he said. “Seeing the way they approached science as purely an adventure and a process of discovery was what really changed the course of my career.”

An early research project for Dr. Wiedenheft involved collecting and studying microbes in Yellowstone National Park. He wanted to understand the ways that viruses manipulate their hosts, and the systems microbes use to defend themselves against infection. As a Montanan who spent as much time as he could outdoors, participating in a major research project and doing it in Yellowstone held a strong appeal. The project ultimately became the subject of his doctorate in 2006.

Click Here to Continue Reading!

Member News

Opio Receives $1.5M Award from National Institutes of Health

Federal grant supports the development of technology that expands the reach of Opioid Treatment Programs into rural and underserved areas

Opio Connect Inc.

September 7, 2023

Opio Connect, Inc., a technology company dedicated to helping Opioid Treatment Programs (OTPs) expand access to treatment, has received a $1.5 million award from the National Institute of Drug Abuse (NIDA), a division of the National Institutes of Health (NIH). The grant will support the development of technology that allows OTPs to serve patients in rural and underserved areas, including correctional facilities. Opio's technology will enable OTPs to serve vast geographic regions within a hub and spoke model, using satellite medication units.

"We are beyond grateful for the NIH's support of American companies building innovative technology to address problems impacting millions of people, such as the need to expand access to OTPs for the treatment of opioid use disorder."

"We are beyond grateful for the NIH's support of American companies building innovative technology to address problems impacting millions of people, such as the need to expand access to OTPs for the treatment of opioid use disorder," said Amber Norbeck, co-founder and CEO of Opio. "This award speaks to Opio's transformative potential, but also highlights the vital role of Opioid Treatment Programs and the power of strategic collaborations and technology to rapidly expand treatment access."

Click Here to Continue Reading!

Inimmune Corporation and Intrommune therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

By Ginger Sewell

January 8, 2024

Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy. The combination of these two approaches is expected to result in the rapid and long-term relief of allergic symptoms resulting from peanut exposure and would be a game changer for patients suffering with this potentially life-threatening allergy.

“The combination provides an opportunity to significantly advance the prevention of allergic symptoms related to exposure to peanut allergen in susceptible individuals. The combination of technologies provided by each company can completely change the treatment paradigm associated with serious food related allergic reactions,” said Alan Joslyn, Ph.D., Inimmune’s CEO. “We look forward to advancing the combined technologies into the clinic in the near future.”

The two companies plan to work together to evaluate the potential for combining the two clinical

stage immunotherapies.

Click Here to Continue Reading!

Paper Spotlight: Bio-inLine Biofilm Reactor and UV LED Treatment


Jan 29, 2024

In a recent dissertation by Carlos Jaser Lara de Larrea, the focus turns to practical solutions for a cleaner water future. The research, titled “Treatment of biofilms and opportunistic pathogens in simulated drinking water distribution systems using UV LEDs,” takes a straightforward approach to tackle biofilm issues in drinking water systems.

At the heart of the study is our Bio-inLine® Biofilm Reactor, a practical tool designed to create a controlled environment for studying biofilms. By tweaking factors like nutrient concentrations and temperature, researchers gain insights into the growth patterns and behavior of biofilms, particularly those in plastic-type pipelines.

The Bio-inLine® Biofilm Reactor isn’t working alone; it shares the stage with the CDC Biofilm Reactor®, another tool making waves in the pursuit of water safety. Together, they’re helping researchers understand biofilm behavior, providing valuable knowledge to combat biofilm proliferation effectively.

However, the real star here is UV LED treatment. As the world leans towards sustainable water treatment methods, UV LED emerges as a promising ally. The research shows that these compact diodes, with their small footprint and versatility, could be a game-changer in inhibiting biofilm formation and eliminating opportunistic pathogens.

Click Here to Continue Reading!

Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

Press Release

January 30, 2024

Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections. NTM infections are most commonly found in the lungs; however, skin and soft tissue, indwelling medical devices, lymph nodes, and blood can also harbor NTM infections.

"We are pleased that the FDA has granted pravibismane this second orphan drug designation for the treatment of NTM infections," said Dr. Jeff Millard, Microbion's Chief Scientific Officer. "Our in vitro and in vivo data for the activity of pravibismane against pulmonary NTM infections and related biofilms, demonstrate unique and highly differentiated, potent activity compared to other agents currently used to treat NTM, while being well tolerated. We look forward to working closely with all our stakeholders and patients to advance the development of pravibismane for the treatment of NTM infections."

"This designation comes at an opportune time as Microbion plans to initiate a Phase 3 program for topical pravibismane treatment of chronic wounds and a Phase 1 program with inhaled pravibismane for treatment of NTM lung infections," said Karim Lalji, Chief Executive Officer. "In an in vivo study using a chronic NTM lung infection model, inhaled pravibismane demonstrated an over 18-fold reduction of M. abscessus, the most pathogenic and rapidly growing species, for which no approved therapy exists. We are encouraged by the potential of pravibismane to address the critical unmet need of NTM infections."

Click Here to Continue Reading!

Braxton Norwood CEO of Lutroo Imaging - Grand Prize winner of AAPM-MIT Hacking Medicine Innovation Challenge

News Provided By EIN Presswire

January 18, 2024

Sana Health and Lutroo Imaging emerged victorious among 70 competing startups and early-stage companies, securing the top honors at the inaugural American Academy of Pain Medicine (AAPM) and MIT Hacking Medicine Innovation Challenge presented by Abbott. Their success grants them the coveted opportunity to collaborate with Michael Hooten, M.D., president of AAPM and professor of Anesthesiology at the Mayo Clinic.

Conducted in a shark tank-style pitch competition at AAPM's 38th Annual Meeting in Scottsdale, Arizona, the Innovation Challenge brought together established startups, aspiring healthcare entrepreneurs, and researchers. The primary objective was to foster advancements that enhance the quality of life for individuals dealing with pain.

Innovation Challenge founder and Co-chair Salman Hirani, MD, expressed the belief that addressing challenges in pain medicine requires the synergy of innovative startups with leaders in clinical practice and research. He emphasized the uniqueness of the event, unprecedented in any national pain medicine organization, and expressed enthusiasm about continuing to support innovation in early-stage companies.

Click Here to Continue Reading!

McLaughlin Research Institute awarded $13.8M grant

By: Tim McGonigal

February 6, 2024

McLaughlin Research Institute vice president MegAnne Casey was thrilled to hear the news that MRI has received $13.8 million from the National Institutes of Health.

“This grant is unprecedented for the research institute,” said Casey.

The grant money will launch the Center for Integrated Biomedical and Rural Health Research or CIB-RHR, expanding the research enterprise over the next five years, with an ultimate hope of bringing healthcare improvements to the state.

“What this allows is for us to recruit faculty, to support the faculty that we do have, and to support studies by Touro and Benefits and Great Falls Clinic,” said Dr. Renee Reijo Pera, MRI President and CEO and Touro College Research Dean.

“It was very competitive, but we came out number one and this will really help change things around here and solidify research as part of part of the Great Falls economic future,” said MRI Board of Directors Chair, Randy Gray.

Click Here to Continue Reading!

Golden Helix Received ISO 13485:2016 Certification

PR Newswire (US)

February 1, 2024

ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. It is specifically tailored to the medical device industry and is recognized globally as a benchmark for ensuring the quality and safety of medical devices.

"We are very pleased to receive ISO 13485:2016 certification. It's a testament to our efforts of continuous quality improvements, including our software development processes, customer success and support processes, and all other operational processes within our company," says Dr. Andreas Scherer, President and CEO of Golden Helix. "ISO 13485:2016 is designed to objectively document that we are holding ourselves to the highest quality standards as we are providing innovative solutions to hospitals, testing labs, and research institutions globally."

In order to be certified, an organization has to maintain a quality management system, demonstrate sufficient risk management, and show consistent tracking of customer satisfaction and safety in the market as well as demonstrate continued improvement efforts on the product and system level.

Click Here to Continue Reading!

Montana/ University News

'Out of the lab into society': MSU gets $6 million research grant

By Patrick Bouman, Bozeman Daily Chronicle 

December 20, 20233

Montana State University plans to use a $6 million grant to help its researchers bring practical uses of their work out into society. The Accelerating Research Translation, or ART, award was given to 18 university teams, totaling over $100 million. The award comes from the National Science Foundation, a federal agency that supports science and engineering research and education.

An undergraduate microbiology student at Montana State University looks into a microscope in the Montana State University Health Sciences Building in 2021 in this file photo. Samuel Wilson/ Chronicle

MSU will receive $6 million through the collaborative partnership over the next four years. The university plans to use the grant to translate its researchers’ findings into the real-world — for example, using immune system research to fight disease or using data on student success to help first-generation students.

The grant will be used in two ways, according to a press release from MSU. The first part includes finding industry experts who can help bring technology made by MSU researchers to market. The second is supporting entrepreneurship through MSU’s Blackstone LaunchPad, which helps faculty and students interested in business innovation.

Click Here to Continue Reading!


By UM News 

December 22, 20233

The University of Montana recently earned a four-year, $4 million Research Evaluation and Commercialization Hub (REACH) award from the National Institutes of Health. The award will establish the L.S. Skaggs Institute for Health Innovation–Research Evaluation and Commercialization Hub (SIHI-REACH).

The UM-based hub will accelerate commercialization of biomedical innovation across Montana, Alaska, Idaho, and Wyoming, as well as help academic innovators develop medical products that address unmet medical needs across the U.S.

Only five such hubs were funded across the country. It will partner with a diverse set of academic institutions – including universities and community, technical and tribal colleges – across the four-state region to train the next generation of biomedical innovators in entrepreneurship and product development.

Click Here to Continue Reading!

Researchers Erica Woodahl (left) and Karen Brown will help boost biomedical innovation across a four-state region with UM’s new research evaluation and commercialization hub.

Montana State receives $26.7 million grant for facility to test and promote quantum technology

By Diana Setterberg, MSU News Service

December 14, 2023

With a new $26.7 million grant from the U.S. Air Force, Montana State University will establish a facility with the mission of moving advanced quantum technology applications in cybersecurity, communications technology and national defense from concept and testing to market.

MSU research engineer Andre Olearain tunes a laser setup in MSU’s Spectrum Lab, which is involved in multiple significant projects to advance quantum communication. MSU photo by Colter Peterson

The 20-month grant from the Air Force Research Laboratory in Rome, New York, will support MSU’s Applied Quantum CORE facility, to be located at the MSU Innovation Campus within the INDUSTRY Bozeman building, which is currently under construction. The grant funding will purchase equipment to test prototype quantum components in the extremely cold environments in which they operate.

Yves Idzerda, a physicist and dean of MSU’s College of Letters and Science who is the grant’s principal investigator and the administrator of MSU’s Applied Quantum CORE, said the new facility will aid the incorporation of quantum science into technological applications to benefit the government and private sectors. CORE stands for Capacity and Operational Resilience and regional Equity.

Click Here to Continue Reading!


By Kelly Mulcaire, UM News Service 

December 27, 2023

Working every day with your best friend would be a dream come true for some people. Getting to work with your best friend to provide a vital service to your hometown community would make it even more special.

For University of Montana alums Stacy Conrow-Ververis and Laurel Chambers that dream is a reality. The lifelong best friends are the CFO and CEO, respectively, of Mineral Community Hospital in Superior, where they were born and raised. The hospital is the main provider of health care in Mineral County and offers a 24-hour emergency room for rural residents. The next closest option is about an hour away in Missoula, so the duo knows how important their hospital is to the community.

“It’s our parents, it’s our friends’ parents, it’s our family,” Chambers said of the patients they serve. “If you had to run your parents to the ER in Missoula, that would be terrible.”

Considering they both agree that getting to work side by side is a rewarding part of their job, it’s not so surprising, then, that they both decided to attend UM for college.

Chambers studied athletic training with plans to pursue a career in physical therapy. Conrow-Ververis earned her degree in elementary education while commuting from Superior each day. Even as busy full-time students, the friends still made time to catch up. 

Click Here to Continue Reading!

UM alums and lifelong best friends Stacy Conrow-Ververis, left, and Laurel Chambers are the CFO and CEO, respectively, of Mineral Community Hospital in their hometown of Superior. (UM photo by LeAnn Layton)

Montana Innovation Partnership at MSU to host virtual conference March 7

From MSU News Service

FEBRUARY 6, 2024

The Montana Innovation Partnership at Montana State University’s TechLink Center will host “Innovate Here,” a one-day virtual conference March 7 focused on key technology industries in Montana, such as bioscience, photonics and quantum technologies.  

The conference aims to connect Montana and regional entrepreneurs who are working on advanced technology with information that can aid in commercializing new research, said Ann Peterson, program director of MSU’s Montana Innovation Partnership

“The Innovate Here’ conference is an opportunity to bring together scientists and industry partners to highlight some of the deep technologies that are driving Montana’s tech industry,” Peterson said. “Entrepreneurs from Montana and across the country will be able to learn about some of these advancements, connect with other entrepreneurs and regional partners, and hear about how to tap into some of the federal investments in research and development for new commercial innovations through America’s Seed Fund and other programs.” 

Conference attendees will hear from Alison Harmon, MSU’s vice president for research and economic development; Bob Sutor, vice president at quantum information company Infleqtion; and Clarice Aiello, director of UCLA’s Quantum Bio Lab; as well as leaders from Montana’s bioscience and photonics sectors.  

Click Here to Continue Reading!

Montana State doctoral student secures prestigious NIH fellowship 

By Skip Anderson, MSU News Service

February 12, 2024

The National Institutes of Health recently awarded a Montana State University doctoral student a prestigious Graduate Partnership Program Fellowship. 

Through the fellowship, Jonathan Shikany, a second-year doctoral student in MSU’s Department of Chemical and Biological Engineering in the Norm Asbjornson College of Engineering, will receive funding for tuition and living expenses as he completes his degree, as well as funding to cover research-related expenses.   

“I feel very fortunate to get guaranteed funding for my Ph.D.,” said Shikany, a native of Bellingham, Washington.    

Shikany works in the lab of his doctoral adviser, Brent Peyton, in MSU’s Department of Chemical and Biological Engineering.  

“John has been exceptional at developing strong research relationships with a variety of national and international collaborators,” Peyton said. Those collaborators include researchers at the U.S. Geological Survey, NIH’s Rocky Mountain Laboratories and Australia’s national laboratory, the Commonwealth Scientific and Industrial Research Organisation. “His balance of field work and laboratory work are yielding a number of interesting new results that we anticipate publishing in peer-reviewed journals over the next few years.”  

Click Here to Continue Reading!

Industry News

Congressional action BIO wants to see in 2024

By Tom Popper

January 26, 2024 

As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.

BIO’s interests include issues like regulation of pharmacy benefit managers (PBMs), R&D tax exemptions, “mitigating” IRA policies that disincentivize investment in rare diseases and small molecule therapies, support for new antimicrobials, reauthorizing the Farm Bill, and pandemic preparedness.

“For the second and final year of the 118th Congress, we will continue our advocacy as we started last year, working to advance legislative priorities that cross BIO’s diverse membership,” said Aiken Hackett, VP of Federal Government Relations for BIO.

As always, BIO is dealing with a broad range of legislative issues, but some of the key issues for 2024 are as follows: PBM legislation, R&D amortization, Addressing IRA’s impact on developing orphan drugs and small molecule drugs, The Pandemic All-Hazards Preparedness Act (PAHPA) Reauthorization, A Farm Bill, Battling Antimicrobial Resistance (AMR), and Rare Pediatric Disease Priority Review Voucher Program.

 Click Here to Read About These Legislative Issues!

What's Happening?

Montana BioScience Alliance

ICYMI - At the annual meeting of the Montana BioScience Alliance, we were joined by three new board members, Monica Serban, Director of the Biotechnology Center at the University of Montana, Kole Mickolio, CEO TitinKm Biomedical, Bozeman, and Blake Wiedenheft, Professor, Department of Microbiology and Cell Biology, Montana State University. Elected to the Executive Board were Cynthia Tsai, President, Ron Zook, Vice President. Corbin Schwanke, Secretary and Carol Beam, Treasurer. Congratulations to all.

The BIO International Convention is scheduled for June 3-6, 2024, in San Diego California. Montana BioScience Alliance will have an exhibit booth. Please plan to participate with us.

Events Calendar

The Innovate Here Conference aims to bring together early-stage technology startups specializing in disruptive innovations in bio, photonics, and quantum technologies. The conference is designed to provide a platform for networking, knowledge exchange, and collaboration among entrepreneurs, researchers, support organizations, and industry experts.

The InnovateHere Conference is brought to you by the Montana Innovation Partnership powered by MSU TechLink Center. This event aims to bring together early-stage technology startups specializing in disruptive innovations in bio, photonics, and quantum technologies. The conference is designed to provide a platform for networking, knowledge exchange about America's Seed Fund and other funding strategies, and collaboration among entrepreneurs, researchers, support organizations, and industry experts. For more information, Click Here!


 Join us for Life Science Innovation Northwest (LSINW) 2024!

LSINW is the can't miss event for the Pacific Northwest's life sciences community. No other local life sciences event brings together CEOs, investors, public and private life sciences organizations, research institutions, scientists, entrepreneurs, and the global health community for outstanding programming and high-quality, executive-level networking. 

This year's conference includes keynote speakers, panel discussions, a fastpitch showdown, poster presentations, and multi-track company presentation sessions which provide a stage for our region’s most promising and influential companies and institutions to showcase their latest innovations and gain additional exposure to investors and potential strategic partners in attendance.


International trade & investment are essential to Montana’s economy— from wheat to SaaS products and everything in between, Montanans are selling their products & services around the world, importing supply chain solutions, and receiving investment from global markets. Come join us to celebrate Montana’s successes on the global stage, learn about untapped opportunities, and gather together in celebration of world trade


Current agenda includes:

Gleaning insights on a dynamic global trade landscape from Ambassador Baucus, unveiling results of the MWTC Annual World Trade & Investment report, honoring the Montana Exporter of the Year as chosen by the Montana District Export Council, inviting Consuls General from our trading partner nations to share insights, meet with businesses and amass more granular detail about mutually beneficial trade and investment opportunities between Montana and their home country, offering timely training for Montana’s exporting and importing firms.’

Join us on May 22nd from 12:30pm to 7:00pm at Montana State University, with a reception to follow. Please see a draft of the current agenda Here! For further questions, please email [email protected].

Register Here!
Register Here!
Employment and Funding Opportunities

Administrative Supplements to Promote Diversity in Research and Development Small Businesses - SBIR/STTR

Are you interested in supporting more diversity and inclusion in your biotechnology? The National Institute on Aging (NIA) Small Business Program is accepting applications for Diversity Supplements, which are administrative funds (up to $250,000 in direct costs) to enhance the research and entrepreneurial workforce's diversity by recruiting and supporting students, post-docs, and eligible investigators from underrepresented groups in health-related research into the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. 

Scientists, entrepreneurs, and trainees from diverse backgrounds and life experiences bring unique perspectives, creativity, and individual enterprise to address complex scientific problems. Participation by minority, socially and economically disadvantaged, and women-owned small businesses is critical to the success of the SBIR and STTR programs as well as to the development of new treatments, technologies, and products that address healthy aging. NIA strives to identify, develop, and support researchers by fostering diversity in the workforce through the SBIR and STTR programs and encourages you to consider applying for the Administrative Supplements to Promote Diversity in Research and Development Small Businesses - SBIR/STTR.

  • Deadline: NIA accepts applications on a rolling basis. Applications received by the second Thursday of the month will be reviewed the following month. Applications received after the second Thursday of the month will be reviewed within two months.

  • Eligibility: Phase I and Phase II SBIR and STTR applicants are encouraged to apply for diversity supplements. At the time of supplement application, parent SBIR and STTR grants must have a minimum of 8 months remaining to ensure sufficient time and opportunity for diversity-based candidates to gain experience. 

  • Candidates: High school, undergraduate, post-baccalaureate, master’s, Ph.D., postdoctoral, and eligible new investigator candidates from groups that are underrepresented in biomedical research, such as individuals from underrepresented racial/ethnic groups, with a disability, or from disadvantaged backgrounds. 

Thank you again for your interest in the NIA SBIR and STTR programs. Please follow us on LinkedIn and Twitter to join the conversation and our NIA Small Business community. For more information, please contact Armineh Ghazarian.

The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The application due dates are January 5th, April 5th and September 5th, so start preparing your application today. As usual, there are four Omnibus Solicitations:

  • PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

  • PA-23-231: PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

  • PA-23-232: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

  • PA-23-233: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

Please note: The SBIR and STTR Extension Act of 2022 (the Act), signed into law by President Biden on September 30, 2022, reauthorized the SBIR program, the STTR program, and related pilot programs through September 30, 2025.

The Act includes major changes to the SBIR and STTR programs, including:

Additionally, peer review criteria have changed. As these are significant changes, applicants are urged to read the solicitations in full.

Questions? Contact [email protected].

2024 FAST Micro-Grants are here!

The Montana Innovation Partnership (MTIP) powered by MSU TechLink Center will utilize some of our 2024 FAST funds to provide financial assistance to Montana small businesses that are actively preparing SBIR/STTR proposals in the federal fiscal year 2024.

The costs to apply for an SBIR/STTR grant or contract can be considerable. Financial assistance for early-stage companies increases their participation in the SBIR program and the quality of their proposals.

MTIP will award six FAST Microgrants to eligible SBIR/STTR applicants of up to $2,000 per year. Prospective SBIR/STTR applicants may apply to MTIP to receive Microgrants to attend conferences, travel to speak with agencies or commercialization partners, to acquire consulting services from an approved service provider for assistance with preparation of Phase I or Phase II proposals, to develop supporting project data, and to undertake other activities directly related to their SBIR/STTR proposal.

For more information and to access the application

Click Here!

Careers at Mesa

Our 500+ employees do work that matters in following our purpose Protecting the Vulnerable®, applying our skills in ways that make a positive impact. That work is accomplished by rallying behind Mesa’s vision: a customer-focused, lean-based value system, called The Mesa Way! and is based on four pillars that drive our work every day- Measure What Matters, Empower Teams, Steadily Improve, and Always Learn

Open Positions:

-Lead Machine Operator (A&P)

-Shipping Assistant I

-Technician - Floater

-Lead - Technician (A&P)

-Shipping Assistant I

-Machine Operator I

-Technician - Mail-in Spore Testing (MIST)

-Production Maintenance Intern

-Manufacturing Engineering Intern

-Technician - Mail-in Spore Testing (MIST)

-Technician - Assembly & Packaging

-Director of R&D and Laboratory Services

To find out more about the current open positions and about Mesa Labs, Click Here!

Careers at FYR Diagnostics

FYR Diagnostics is a fast growing Missoula, MT-based biotechnology company developing a powerful portfolio of PCR-focused solutions. FYR Diagnostics’ mission is to commercialize novel detection technologies to help eliminate human suffering by better diagnosing human disease states and to eliminate vast inefficiencies in the agricultural industry.

Those who work with FYR Diagnostics are members of a community that seeks to respect and celebrate all the qualities that make each of us unique. Each of us is empowered to be ourselves within this community, which cultivates and promotes equity, diversity, and inclusion at all levels. FYR Diagnostics is proud to be an Equal Opportunity Workplace and Affirmative Action Employer.

To find out more about the current open positions, Click Here!

Two Bear Capital provides a job board with the different job openings from

the following companies:

-Abilita Bio



-FYR Diagnostics



-Novoron Bioscience


-Selector AI


For Open positions with Companies you'll love to work for, Click Here!

Work for a great company in beautiful Bozeman, MT

At Golden Helix, we are committed to accelerating ground-breaking research in genetics, drug discovery and predictive analytics, to our purpose of dramatically improving human health, our great culture, personal development, and strong values.

We are always seeking self-motivated individuals who strive for excellence and have the drive to help us on our journey. We offer competitive wages, benefits and the opportunity to live in one of the most beautiful areas in the world.

Open Positions:

-Area Sales Director

-Director of Renewal Sales

-Finance Manager

-Operations Coordinator

General Employment Inquiries

Interested in a position that we're not actively hiring? Submit your resume for our files! We will archive your information and if a position becomes available that matches your qualifications, we'll contact you.

Click here to apply!

GSK Hamilton

The Hamilton site is located on a 35-acre campus in the heart of the scenic Bitterroot Valley of western Montana. It started in 1981 as Ribi ImmunoChem Research, Inc., a company focused on research and development of vaccine components capable of stimulating the immune system. GSK purchased the site in 2005 to acquire its proprietary adjuvant technology which is used to help make vaccines more effective. GSK Hamilton currently employs over 185 professionals and is expanding its job base with the addition of a new adjuvant manufacturing facility.

To review current openings at the GSK Hamilton (GlaxoSmithKline) site, Click Here!

Open Solicitations From Techlink and MTIP

Dates are subject to change. Please refer to each agency site for up-to-date information.

  • NIH Targeted funding announcements have varying release and due dates. Find a list of currently open program announcements and requests for applications here.

Identify a participating agency or agencies interested in your topic area, Click Here.

Different participating agencies fund different sectors and technology areas, so a first step is to see which agency or agencies fund projects relevant to you. Agencies also differ in how narrow or broadly they define their topic areas. Current Topics - Search technology topic areas that agencies are interested in funding right now.

Reach out today for no-cost consulting and proposal reviews from one of MTIP's SBIR


Montana SBIR/STTR Matching Funds Program

What do you do after you have received Stage 1 SBIR/STTR matching funds from the Montana Department of Commerce, have satisfactorily completed your Phase I work, the Phase I final report has been accepted by the Federal SBIR/STTR agency, and you have submitted your SBIR or STTR Phase II proposal?

You submit your Stage 2 application to the Montana SBIR/STTR Matching Funds Program. You do not have to receive notification of a Phase II award before submitting this application. For more information, Click Here!

Questions? Feel free to contact Ann at [email protected] or

Annmarie Robinson with the Department of Commerce at [email protected].

How would you like to have more free time to focus on innovating and growing your business?
Are you ready to clear your plate of time-consuming daily HR tasks — such as payroll, benefits, talent, and compliance? Right now's the perfect time to see if ADP’s PEO is the right move for you, too.
What is ADP TotalSource?
  • Endorsed by BIO for life science companies of any size.
  • Full-service PEO (professional employer organization) partner with coverage in all 50 states
  • Partner to help you attract and retain top talent more easily with access to ADP Recruiters, HR advisors and best-in-class benefits.
  • Industry-leading PEO, giving you confidence that ADP does it the right way.
As an IRS certified and ESAC accredited PEO, ADP meets the highest standards for financial responsibility, ethical business conduct, and regulatory compliance.
Now is the time to start the process if you want to make a change for 2024.
Learn More!

UPS Healthcare brings reliability, scalability and security to life science companies every day. Its portfolio of end-to-end services is well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Learn exactly how from UPS Healthcare.

Through Montana BioScience Alliance’s partnership with UPS Healthcare, you get access to exclusive rates on a full suite of UPS® services. And, after recent renegotiations, the savings have gotten even better. While the same popular shipping services, like UPS Next Day Air®, and UPS Worldwide Express SM, remain at reduced rates, the price band range to qualify for discounts is narrower. For example, a company that spends $1,500 to $4,999.99 weekly for UPS Next Day Air® shipping now receives a 60% discount rather than a 50-55% discount under the previous arrangement.

As a Montana BioScience Alliance member, be confident that your critical healthcare shipments will be delivered timely and with care by a quality-focused and patient-driven organization.

Montana BioScience Alliance Members Save Up To:

· 74% on UPS Next Day Air®

· 59% on UPS 2nd Day Air® & UPS 3 Day Select Services®

· 51% on UPS Ground® Commercial Services

· 68% on UPS Worldwide International Services

BIO Business Solutions®, the largest cost-savings program for the life sciences industry, is FREE with your company’s membership in BIO or Montana BioScience Alliance. Receiving savings from our lab and office partners is incredibly simple. We’ve already vetted the suppliers and negotiated discounted pricing and favorable end-user agreements.

Click on the company name to learn more.
There is no fee for MBA members to participate.

Montana BioScience Alliance | []


The Montana Bioscience Alliance serves as a hub for Montana's biotechnology companies,

entrepreneurs, laboratories, hospitals, clinics and universities to commercialize, grow and sustain

globally competitive bioscience companies -- ultimately to create high-quality jobs and economic

opportunity in Montana.

Sharon Peterson

Executive Director

Montana BioScience Alliance

[email protected]